High-risk, BCG-unresponsive NMIBC beyond RC: intravesical and systemic therapies скачать в хорошем качестве

High-risk, BCG-unresponsive NMIBC beyond RC: intravesical and systemic therapies

Felix Guerrero-Ramos, MD, PhD, from Hospital Universitario 12 de Octubre in Madrid, Spain, provides insights into non-muscle invasive bladder cancer. He underscores the challenge of relapses, occurring in 50-70% of patients within three to four years of Bacillus Calmette-Guérin (BCG) treatment. Properly defining BCG response is crucial, with responsive tumors indicating a need for radical cystectomy based on Level 3 evidence. Dr Guerrero-Ramos discusses FDA-approved therapies, including pembrolizumab for carcinoma in situ (CIS) BCG-unresponsive tumors and nadofaragene firadenovec for intravesical treatment. He explores promising intravesical therapies like the TARA-200 device and ErdaRIS, which integrates erdafitinib for FGFR-altered tumors. The evolving landscape suggests a future with improved options and approvals, potentially favoring intravesical therapies for their efficacy and favorable toxicity profiles. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR) 2023 in Malaga, Spain. These works are owned by Magdalen Medical Publishing, protected by global copyright laws. All rights are reserved.